Frankfurt - Delayed Quote EUR

Anavex Life Sciences Corp. (12X1.F)

Compare
9.11
-0.08
(-0.87%)
At close: January 31 at 8:16:34 AM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Operating Expense
52,802.00
52,802.00
55,731.00
50,986.00
41,948.00
Operating Income
-52,802.00
-52,802.00
-55,731.00
-50,986.00
-41,948.00
Net Non Operating Interest Income Expense
7,320.00
7,320.00
5,555.00
947.00
26.00
Other Income Expense
2,480.00
2,480.00
2,678.00
2,419.00
4,281.00
Pretax Income
-43,002.00
-43,002.00
-47,498.00
-47,620.00
-37,641.00
Tax Provision
--
--
7.00
358.00
268.00
Net Income Common Stockholders
-43,002.00
-43,002.00
-47,505.00
-47,978.00
-37,909.00
Diluted NI Available to Com Stockholders
-43,002.00
-43,002.00
-47,505.00
-47,978.00
-37,909.00
Basic EPS
-0.52
--
-0.60
-0.62
-0.54
Diluted EPS
-0.52
--
-0.60
-0.62
-0.54
Basic Average Shares
83,468.05
--
79,787.60
76,909.99
69,802.96
Diluted Average Shares
83,468.05
--
79,787.60
76,909.99
69,802.96
Total Operating Income as Reported
-52,877.00
-52,877.00
-55,756.00
-50,986.00
-42,002.00
Total Expenses
52,802.00
52,802.00
55,731.00
50,986.00
41,948.00
Net Income from Continuing & Discontinued Operation
-43,002.00
-43,002.00
-47,505.00
-47,978.00
-37,909.00
Normalized Income
-43,191.00
-43,191.00
-47,473.40
-47,263.84
-37,714.82
Interest Income
7,320.00
7,320.00
6,519.00
947.00
26.00
Interest Expense
--
--
964.00
--
--
Net Interest Income
7,320.00
7,320.00
5,555.00
947.00
26.00
EBIT
-43,002.00
-43,002.00
-46,534.00
-47,620.00
-37,641.00
EBITDA
-43,002.00
-43,002.00
-46,534.00
-47,620.00
-37,641.00
Net Income from Continuing Operation Net Minority Interest
-43,002.00
-43,002.00
-47,505.00
-47,978.00
-37,909.00
Total Unusual Items Excluding Goodwill
189.00
189.00
-40.00
-904.00
-266.00
Total Unusual Items
189.00
189.00
-40.00
-904.00
-266.00
Normalized EBITDA
-43,191.00
-43,191.00
-46,494.00
-46,716.00
-37,375.00
Tax Rate for Calcs
--
--
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
-8.40
-189.84
-71.82
9/30/2021 - 4/28/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

19X.SG Axsome Therapeutics Inc
102.25
-2.01%
 
I9SA.HA Verona Pharma PLC
55.00
+0.92%
 
TRRI Alzex Neuropharma Inc.
0.1980
0.00%
 
HALB Halberd Corporation
0.0034
+13.33%
 
RAPP Rapport Therapeutics, Inc.
16.41
-1.44%
 
ASND Ascendis Pharma A/S
130.66
+2.64%
 
NAMS NewAmsterdam Pharma Company N.V.
22.29
+2.39%
 
PCVX Vaxcyte, Inc.
88.32
-3.95%
 
DAWN Day One Biopharmaceuticals, Inc.
12.37
-3.81%
 
IBIO iBio, Inc.
3.0100
+1.35%